MedTrace Logo

Evolution of Thromboelastography During Tranexamic Acid Treatment

NCT03801122 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2023-05-06

No results posted yet for this study

Summary

Patients with hematological malignancies are at increased risk of bleeding, especially during intensive chemotherapy. The aim of this study is to compare by thromboelastography changes during the intensive chemotherapy in patients with hematological malignancies.

Conditions

  • Hematological Malignancies Treated With Intensive Chemotherapy

Interventions

DRUG

Tranexamic acid

Administration of tranexamic acid, with 3 injections/8 hours.

Sponsors & Collaborators

  • Institut de Cancérologie de la Loire

    collaborator OTHER

  • Centre Hospitalier Universitaire de Saint Etienne

    lead OTHER

Principal Investigators

  • Emilie Chalayer, MD · CHU de Saint-Etienne

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-03-05
Primary Completion
2022-03-09
Completion
2022-07-11

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03801122 on ClinicalTrials.gov